Oramed Pharmaceuticals (ORMP) & The Competition Financial Comparison

Oramed Pharmaceuticals (NASDAQ: ORMP) is one of 191 public companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its competitors? We will compare Oramed Pharmaceuticals to related companies based on the strength of its profitability, valuation, dividends, risk, institutional ownership, earnings and analyst recommendations.

Earnings & Valuation

This table compares Oramed Pharmaceuticals and its competitors revenue, earnings per share and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Oramed Pharmaceuticals $640,000.00 -$10.96 million -9.53
Oramed Pharmaceuticals Competitors $213.24 million -$39.02 million -64.32

Oramed Pharmaceuticals’ competitors have higher revenue, but lower earnings than Oramed Pharmaceuticals. Oramed Pharmaceuticals is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.


This table compares Oramed Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Oramed Pharmaceuticals N/A -54.96% -29.63%
Oramed Pharmaceuticals Competitors -3,379.38% -92.80% -39.19%

Institutional and Insider Ownership

1.7% of Oramed Pharmaceuticals shares are owned by institutional investors. Comparatively, 46.5% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 27.5% of Oramed Pharmaceuticals shares are owned by insiders. Comparatively, 14.7% of shares of all “Biotechnology & Medical Research” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Volatility & Risk

Oramed Pharmaceuticals has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500. Comparatively, Oramed Pharmaceuticals’ competitors have a beta of 1.48, suggesting that their average share price is 48% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Oramed Pharmaceuticals and its competitors, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oramed Pharmaceuticals 0 0 1 0 3.00
Oramed Pharmaceuticals Competitors 512 2429 6611 122 2.66

Oramed Pharmaceuticals presently has a consensus target price of $25.00, indicating a potential upside of 176.24%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 17.90%. Given Oramed Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts clearly believe Oramed Pharmaceuticals is more favorable than its competitors.


Oramed Pharmaceuticals beats its competitors on 8 of the 12 factors compared.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc. (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection. Oramed’s delivery platform protects protein sand enhances their absorption, allowing them to reach the blood stream through the portal vein. The Company’s products include ORMD-0801, Oral insulin capsule; ORMD 0901, Oral Exenatide capsule; and combination therapy of ORMD 0801 + ORMD 0901. ORMD-0801 is under phase II A clinical trials. ORMD-0901 is under preclinical/Investigational New Drug (IND) stage under phase I B.

Receive News & Ratings for Oramed Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply